Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer — Kerry Jewell (2025) | RDL Network
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Article 2025 en
Authors
KJ
Kerry Jewell
JB
James Buteau
EM
Elizabeth Medhurst
Abstract
1 min read
Current randomized controlled data ([1][1] , [2][2]) demonstrate the safety and efficacy of 6 cycles of [177Lu]Lu-PSMA-617 therapy in men with metastatic castration-resistant prostate cancer. In our first phase 2 trial ([3][3]), 15 of 30 patients received additional cycles; 11 (73%) had a subsequent
Michael S. Hofman, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M. Joshua, David A. Pattison, Jeffrey C. Goh, Ian Kirkwood, Thean Hsiang Tan, Roslyn J. Francis, Siobhan Ng, Natalie Rutherford, Craig Gedye, Andrew M. Scott, Sze-Ting Lee, Andrew Weickhardt, Shakher Ramdave, Edmond M. Kwan, Arun Azad, W A Macdonald, Andrew D. Redfern, Alison Y. Zhang, Martin R. Stockler, Andrew Martin, Ian D. Davis
Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua, David A. Pattison, Roslyn J. Francis, Scott Williams, Shahneen Sandhu, Ian D. Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G. Murphy, Michael S. Hofman, Arun Azad
Michal Eifer, Duncan E. K. Sutherland, Isaac Goncalves, James Buteau, Lewis Au, Arun Azad, Louise Emmett, Grace Kong, Louise Kostos, Aravind S. Ravi Kumar, Edmond M. Kwan, Elizabeth Medhurst, Shahneen Sandhu, Ben Tran, Alexander W. Wyatt, Michael S. Hofman
Duncan E. K. Sutherland, Raghava Kashyap, Price Jackson, James Buteau, Declan G. Murphy, B.D. Kelly, Lavinia Spain, Shahneen Sandhu, Arun Azad, Elizabeth Medhurst, Grace Kong, Michael S. Hofman
Shahneen Sandhu, Anthony M. Joshua, Louise Emmett, Lavinia Spain, Lisa G. Horvath, Megan Crumbaker, A. Antón, Roslyn Wallace, Anupama Pasam, Mathias Bressel, E. Cassidy, Patricia Banks, Nattakorn Dhiantravan, Timothy Akhurst, Aravind Ravi Kumar, Ramin Alipour, Mark Scalzo, Scott Williams, Rodney J. Hicks, Michael S. Hofman
Discussion(0)
No comments yet. Be the first to comment.